| Eligibility |
Inclusion Criteria:
1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of
screening. There must be no less than 20% female participants in the Treatment Phase.
2. Male and female participants who are overtly healthy. Healthy is defined as no
clinically relevant abnormalities identified by a detailed medical history, full
physical examination, vital signs, 12-lead ECG, and/or clinical laboratory tests.
3. Participants must have drug abuse experience with opioids; ie, must have used opioids
for non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions
within the last year and at least once in the 8 weeks before the Screening Visit
(Visit 1).
4. Participants must satisfactorily complete both the Naloxone Challenge and the Drug
Discrimination.
5. Participants who are willing and able to comply with all scheduled visits, treatment
plan, laboratory tests, lifestyle considerations, and other study procedures.
6. Body mass index (BMI) of 17.5 to 34 kg/m2, inclusive; and a total body weight
=50 kg (110 lb).
7. Capable of giving signed informed consent, which includes compliance with the
requirements and restrictions listed in the informed consent document (ICD).
Exclusion Criteria:
1. Current or past diagnosis of any type of drug dependence within the past year.
Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine)
will be assessed by the Investigator using the Diagnostic and Statistical Manual-4
(DSM-4) criteria performed at Screening. Current drug use will be allowed if the
candidate can produce a negative urine sample and are free of any signs/symptoms of
withdrawal. The candidate will be informed if they have a positive breathalyzer test.
2. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).
3. Any condition possibly affecting drug absorption (eg, gastrectomy) excluding
cholecystectomy within 1 year prior to study.
4. Abnormal baseline EtCO2 <35mm Hg or >45 mm Hg.
5. Clinical or laboratory evidence of active hepatitis A infection or a history of human
immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C and/or positive
testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody
(HBcAb), or hepatitis C antibody (HCVAb).
6. Participants with active suicidal ideation or suicidal behavior within 5 year prior to
Screening as determined through the use of the Columbia-Suicide Severity Rating Scale
(C-SSRS) or active ideation identified at Screening or on Day 0.
7. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the participant inappropriate for entry into
this study.
8. Patients with: sleep apnea, myasthenia gravis and glaucoma.
9. Use of prescription or nonprescription drugs and dietary supplements within 7 days or
5 half-lives (whichever is longer) prior to the first dose of investigational product.
10. Herbal supplements and herbal medications must be discontinued at least 28 days prior
to the first dose of study medication.
11. Previous administration with an investigational drug within 30 days (or as determined
by the local requirement) or 5 half-lives (whichever is longer) preceding the first
dose of investigational product used in this study.
12. Positive urine drug screen (UDS) for substances of abuse at each admission in the
Qualification and Treatment Phase, excluding tetrahydrocannabinol (THC). If a
participant presents with a positive UDS excluding THC at any admission or any visit,
the investigator, at his/her discretion, may reschedule a repeat of UDS until the UDS
is negative, excluding THC, before the participant is permitted to participate in any
phase of the study.
13. Unable to abstain from using THC during the Qualification and Treatment Phase of the
study.
14. Has participated in, is currently participating in, or is seeking treatment for
substance-and/or alcohol-related disorders (excluding nicotine and caffeine).
15. Has a positive alcohol breathalyzer or urine test at each admission to the study
center during qualification and treatment phase. Positive results may be repeated
and/or participants re-scheduled at the Investigator's discretions.
16. Participants are heavy smokers or users of other types of nicotine products (>20
cigarettes equivalents per day).
17. Participants are unable to abstain from smoking for at least 2 hours before and at
least 8 hours after study drug administration.
18. Screening sitting blood pressure (BP) =140 mm Hg (systolic) or =90 mm Hg (diastolic),
following at least 5 minutes rest. If BP is =140 mm Hg (systolic) or
=90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3
BP values should be used to determine the participant's eligibility. Repeated BP tests
should be spaced at least 5 minutes apart.
19. Baseline (screening) 12-lead electrocardiogram (ECG) that demonstrates clinically
relevant abnormalities that may affect participant safety or interpretation of study
results (eg, baseline corrected QT (QTc) interval as determined by the Fridericia
method (QTcF) >450 msec, complete left bundle branch block [LBBB], signs of an acute
or indeterminate-age myocardial infarction, ST-T interval changes suggestive of
myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious
bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450
msec, this interval should be rate-corrected using the Fridericia method and the
resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450
msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average
of the 3 QTcF or QRS values should be used to determine the participant's eligibility.
Computer-interpreted ECGs should be overread by a physician experienced in reading
ECGs before excluding participants.
20. Participants with ANY of the following abnormalities in clinical laboratory tests at
screening, as assessed by the study-specific laboratory and confirmed by a single
repeat test, if deemed necessary: Aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) level 1.5 × upper limit of normal (ULN); Total bilirubin level
=1.5 × ULN; participants with a history of Gilbert's syndrome may have direct
bilirubin measured and would be eligible for this study provided the direct bilirubin
level is = ULN.
21. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
within 60 days prior to dosing.
22. History of sensitivity to heparin or heparin-induced thrombocytopenia.
23. Unwilling or unable to comply with the criteria in the Lifestyle Considerations
section of this protocol.
24. History of hypersensitivity to pregabalin or oxycodone or any of the components in the
formulation of the study products.
25. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
Sponsor employees, including their family members, directly involved in the conduct of
the study.
|
